Outpatient care for opioid use disorder among the commercially insured: Use of medication and psychosocial treatment.
Journal
Journal of substance abuse treatment
ISSN: 1873-6483
Titre abrégé: J Subst Abuse Treat
Pays: United States
ID NLM: 8500909
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
30
08
2019
revised:
07
05
2020
accepted:
19
05
2020
entrez:
1
7
2020
pubmed:
1
7
2020
medline:
29
7
2021
Statut:
ppublish
Résumé
Evidence-based outpatient treatment for opioid use disorder (OUD) consists of medications that treat OUD (MOUD) and psychosocial treatments (e.g., psychotherapy or counseling, case management). Prior studies have not examined the use of these components of care in a commercially insured population. We analyzed claims data from a large national commercial insurer of enrollees age 17-64 identified with OUD (2008-2016, N = 87,877 persons and 122,708 person-years). Multinomial logistic regression models identified factors associated with receiving in a given year: 1) both MOUD and psychosocial visits, 2) MOUD without psychosocial visits, 3) psychosocial visits without MOUD, or 4) neither. We estimated predicted probabilities for key variables of interest. Identification of OUD nearly tripled during the observation period (0.17% in 2008, 0.45% in 2016). Among person-years identified as having OUD, 36.3% included MOUD (8.1% both MOUD and psychosocial visits and 28.2% MOUD without psychosocial visits). In adjusted analyses, women had a lower probability of receiving either treatment alone or in combination (e.g.,MOUD plus psychosocial visits: women = 6.7% [6.5%-6.9%] vs. men = 9.2% [9.0%-9.4%]). Moderate/severe vs. mild OUD was associated with a higher probability of receiving MOUD (e.g., MOUD plus psychosocial visits: 8.7% [8.6%-8.9%] vs. 0.9% [0.7%-1.0%]). In contrast, an OUD overdose was associated with a greater probability of receiving neither treatment (78.2% [77.4%-79.0%] vs. 55.5% [55.2%-55.8%]). Over time, the probability of receiving each MOUD and psychosocial treatment category increased relative to 2008, but reached a peak and then plateaued or declined, by the end of the study period. A significant treatment gap exists among individuals identified with OUD in this commercially insured population, with greater risks of receiving no treatment for women and for individuals with mild versus moderate or severe OUD. Overdose is associated with receiving neither MOUD nor psychosocial treatment. While treated prevalence initially increased relative to 2008, rates of treatment subsequently plateaued. Additional study and monitoring to elucidate barriers to OUD treatment in commercially insured populations are warranted.
Sections du résumé
BACKGROUND
Evidence-based outpatient treatment for opioid use disorder (OUD) consists of medications that treat OUD (MOUD) and psychosocial treatments (e.g., psychotherapy or counseling, case management). Prior studies have not examined the use of these components of care in a commercially insured population.
METHODS
We analyzed claims data from a large national commercial insurer of enrollees age 17-64 identified with OUD (2008-2016, N = 87,877 persons and 122,708 person-years). Multinomial logistic regression models identified factors associated with receiving in a given year: 1) both MOUD and psychosocial visits, 2) MOUD without psychosocial visits, 3) psychosocial visits without MOUD, or 4) neither. We estimated predicted probabilities for key variables of interest.
RESULTS
Identification of OUD nearly tripled during the observation period (0.17% in 2008, 0.45% in 2016). Among person-years identified as having OUD, 36.3% included MOUD (8.1% both MOUD and psychosocial visits and 28.2% MOUD without psychosocial visits). In adjusted analyses, women had a lower probability of receiving either treatment alone or in combination (e.g.,MOUD plus psychosocial visits: women = 6.7% [6.5%-6.9%] vs. men = 9.2% [9.0%-9.4%]). Moderate/severe vs. mild OUD was associated with a higher probability of receiving MOUD (e.g., MOUD plus psychosocial visits: 8.7% [8.6%-8.9%] vs. 0.9% [0.7%-1.0%]). In contrast, an OUD overdose was associated with a greater probability of receiving neither treatment (78.2% [77.4%-79.0%] vs. 55.5% [55.2%-55.8%]). Over time, the probability of receiving each MOUD and psychosocial treatment category increased relative to 2008, but reached a peak and then plateaued or declined, by the end of the study period.
CONCLUSIONS
A significant treatment gap exists among individuals identified with OUD in this commercially insured population, with greater risks of receiving no treatment for women and for individuals with mild versus moderate or severe OUD. Overdose is associated with receiving neither MOUD nor psychosocial treatment. While treated prevalence initially increased relative to 2008, rates of treatment subsequently plateaued. Additional study and monitoring to elucidate barriers to OUD treatment in commercially insured populations are warranted.
Identifiants
pubmed: 32600627
pii: S0740-5472(20)30296-8
doi: 10.1016/j.jsat.2020.108040
pmc: PMC7687676
mid: NIHMS1598002
pii:
doi:
Substances chimiques
Buprenorphine
40D3SCR4GZ
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
108040Subventions
Organisme : NIDA NIH HHS
ID : P30 DA035772
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Références
Health Aff (Millwood). 2016 Dec 1;35(12):2289-2296
pubmed: 27920318
Fed Regist. 2016 Jul 8;81(131):44711-39
pubmed: 27400463
Lancet. 2019 Apr 27;393(10182):1760-1772
pubmed: 30878228
Ann Intern Med. 2017 Sep 05;167(5):293-301
pubmed: 28761945
J Addict Dis. 2016;35(1):22-35
pubmed: 26467975
Addiction. 2006 Mar;101(3):404-12
pubmed: 16499513
J Subst Abuse Treat. 2014 Feb;46(2):87-97
pubmed: 24075796
Am J Public Health. 2018 May;108(5):642-648
pubmed: 29565661
J Gen Intern Med. 2019 Dec;34(12):2723-2725
pubmed: 31090029
J Addict Med. 2018 Jul/Aug;12(4):287-294
pubmed: 29601307
J Gen Intern Med. 2017 Jun;32(6):660-666
pubmed: 28194688
MMWR Morb Mortal Wkly Rep. 2016 Jan 01;64(50-51):1378-82
pubmed: 26720857
J Gen Intern Med. 2019 Jun;34(6):789-791
pubmed: 30693436
J Stud Alcohol Drugs. 2013 Mar;74(2):258-65
pubmed: 23384373
J Subst Abuse Treat. 2018 Feb;85:90-96
pubmed: 28733097
J Subst Abuse Treat. 2016 Oct;69:64-71
pubmed: 27568512
Ann Intern Med. 2018 Aug 7;169(3):190-192
pubmed: 29913514
Psychiatr Clin North Am. 2010 Jun;33(2):339-55
pubmed: 20385341
JAMA. 1993 Apr 21;269(15):1953-9
pubmed: 8385230
J Health Econ. 2018 Jul;60:177-197
pubmed: 29990675
Drug Alcohol Depend. 2017 Apr 01;173 Suppl 1:S48-S54
pubmed: 28363320
Am J Public Health. 2015 Aug;105(8):e55-63
pubmed: 26066931
Addict Behav. 2010 Nov;35(11):1001-7
pubmed: 20598809
J Subst Abuse Treat. 2016 Feb;61:47-59
pubmed: 26531892
J Manag Care Spec Pharm. 2019 May;25(5):612-620
pubmed: 31039058
J Subst Abuse Treat. 2016 Jul;66:48-53
pubmed: 27211996
Addict Sci Clin Pract. 2019 Aug 15;14(1):31
pubmed: 31416475
Am J Psychiatry. 2017 Aug 1;174(8):738-747
pubmed: 27978771
Soc Work Public Health. 2013;28(3-4):165-74
pubmed: 23731411
Med Care. 2018 Jun;56(6):505-509
pubmed: 29668645
BMJ. 2017 Apr 26;357:j1550
pubmed: 28446428
Ann Intern Med. 2018 Aug 7;169(3):137-145
pubmed: 29913516
Health Aff (Millwood). 2018 Dec;37(12):1940-1947
pubmed: 30633671
Addiction. 2017 Aug;112(8):1329-1336
pubmed: 28044376
N Engl J Med. 2020 Apr 2;382(14):1289-1290
pubmed: 32242351
Cochrane Database Syst Rev. 2011 Sep 07;(9):CD005031
pubmed: 21901695
Addict Behav. 2011 Jun;36(6):584-589
pubmed: 21377275
Drug Alcohol Depend. 2020 Apr 1;209:107952
pubmed: 32172130
J Addict Dis. 2016 Oct-Dec;35(4):305-314
pubmed: 27192330
Drug Alcohol Depend. 2013 Jan 1;127(1-3):59-64
pubmed: 22770461
JAMA. 2015 Oct 13;314(14):1468-78
pubmed: 26461997
J Clin Psychiatry. 2016 Jun;77(6):772-80
pubmed: 27337416
J Psychoactive Drugs. 2017 Apr-Jun;49(2):102-110
pubmed: 28350229
J Subst Abuse Treat. 2016 Jul;66:23-9
pubmed: 27211993
JAMA. 2017 Aug 22;318(8):750-752
pubmed: 28829862
JAMA. 2000 Oct 4;284(13):1689-95
pubmed: 11015800
Psychiatr Serv. 2017 May 1;68(5):462-469
pubmed: 28045350
Am J Psychiatry. 2008 Feb;165(2):179-87
pubmed: 18198270
J Subst Abuse Treat. 2015 Aug;55:1-5
pubmed: 25921475